Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neisseria meningitidis group W135 oligosaccharide conjugate (CRM197)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Neisseria meningitidis group W135 oligosaccharide conjugate (CRM197) is a specific conjugate vaccine component designed to provide active immunity against meningococcal disease caused by serogroup W-135. It consists of the capsular oligosaccharide of the W-135 strain covalently linked to the CRM197 carrier protein, a non-toxic mutant of the diphtheria toxin. This conjugation process is critical for converting the T-cell independent polysaccharide antigen into a T-cell dependent antigen, which allows for the induction of immunological memory and a robust immune response in infants and young children. This component was primarily developed by Novartis Vaccines (now part of GSK) and is a key constituent of the quadrivalent meningococcal conjugate vaccine Menveo (MenACWY-CRM).
- Other names
- Meningococcal Group W-135 Oligosaccharide ConjugateNeisseria meningitidis serogroup W-135 oligosaccharide conjugate (CRM197)
02
Targets
MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on Neisseria meningitidis group W135 oligosaccharide conjugate (CRM197).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neisseria meningitidis group W135 oligosaccharide conjugate (CRM197).